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Introduction
Diabetics are prone to coronary artery disease (CAD) along with other conditions. Patients with CAD and diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) are at significantly increased risk for short and long term adverse clinical outcomes. 1, 2 The underlying mechanism is due to the more diffuse and accelerated form of atherosclerosis and endothelial dysfunction which lead to diffused coronary lesions, small vessel disease, multi-vessel involvement, larger plaque burden as well as higher incidence of left main and ostial lesions. 3 Diabetic patients respond less favorably to revascularization and have higher restenosis rates. Nevertheless, stent thrombosis (ST) still remains the main safety concern and long term complication associated with the use of both bare metal stents (BMS) and drug eluting stents (DES). The use of effective DES has definitely reduced the restenosis rates and the need for repeat intervention as compared with BMS, which has brought great hope of providing diabetic patients better and longer-lasting interventional solutions. 4e8 Thus, DES has greatly improved clinical outcomes in diabetic patients. Still, smaller vessels (decreased lumen) in diabetic patients remain an important predictor of restenosis even in the era of DES. 9, 10 There may be an increased atherothrombotic risk in DM patients due to hyperglycemia, and an improved glycemic control has been shown to improve blood thrombogenicity.
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Current polymer-based, DES allow for controlled release of therapeutic agents at the site of injury. Most effective drugs utilized with DES for prevention of restenosis up to this point in time have been sirolimus 12e16 and paclitaxel. 17e19 Large cohort studies 8, 20 have reported rates of ST between 0.7% and 1.7% in the first year and <0.6% in subsequent years depending on the type of DES implanted, and the population studied. BioMatrixä-Biolimus A9ä eluting stent (BA9ä) (BioMatrix) is a new generation DES incorporating a biodegradable polymer containing the anti-proliferative drug Biolimus A9ä that is only coated on the abluminal side. The proprietary is a semi-synthetic sirolimus analog and shares a similar adverse event profile when used at equivalent dose levels. It is highly lipophilic, (10 times more than its analogs) rapidly absorbed in tissues, and able to reversibly inhibit growth factorstimulated cell proliferation. With the facts, very highly lipophilic BA9ä and which is coated only on the abluminal surface of the stent assures targeted action of the drug. Moreover, systemic exposure of the drug and the polymer is avoided by this technology. Current data shows that BA9ä on a molecular level forms a complex with the cytoplasmic proteins that inhibit the cell cycle between the G0 and G1 phase. The result is an interruption of the cascade governing cell metabolism, growth, and proliferation. The safety and efficacy of BioMatrix stents has been established in several large randomized controlled trials including LEADERS trial, 21 which showed BA9 TM with biodegradable polymer had 80% relative risk reduction of very late stent thrombosis (1e4 years) when compared to first generation durable polymer DES. This registry was initiated with aim to gather the clinical outcomes of diabetic patients receiving the BioMatrix stents. We captured 1-and 2-year incidence rates of MACE and ST from this multicenter post market surveillance registry.
Methodology
This is a prospective observational study of diabetic patients who underwent implantation of BA9ä eluting stent, 'BioMatrix' conducted at seven interventional cardiology sites in India between April 2009 and December 2011. This prospective study was conducted with prior notification to DCGI and with EC approval of individual centers. Study was registered with clinical trial registry of India with CTRI number: CTRI/2011/10/ 002088. Primary endpoint of this registry was major adverse cardiac events (MACE) defined as composite of cardiac death, myocardial infarction (MI), or target vessel revascularization (TVR) within the study population at 12 months of follow-up. Secondary outcomes were stent thrombosis (ST) at 1, 6 and 12 months and 2 years; Patient oriented composite endpoint defined as any cause mortality, MI, or any clinically driven TVR at 1, 6 and 12 months and 2 years, and total revascularization rate at these time points. However, in this interim analysis, primary endpoint is looked at along with ST. The inclusion criteria for the study were diabetic patients (Type I or Type II diabetes with documented treatment with insulin or oral hypoglycemics or undocumented or newly diagnosed diabetics with either blood sugar fasting value >115 mg/dl, post meal 140 mg/dl or glycosylated hemoglobin >7.3%), eligible for PCI with lesions suitable for stent implantation with age !18 years, presence of !1 coronary artery stenoses in a native coronary artery, saphenous bypass graft or radial vein graft from 2.25e4.0 mm in diameter that can be covered with one or multiple stents. Patients excluded were: patients needing additional stent not of the BA9ä eluting stent type; receiving in addition to the Biolimus eluting stent and/or other coronary vascular interventions like balloon angioplasty; receiving the BioMatrixä stent during index and/or staged procedure and if admitted for treatment of diabetic ketoacidosis !2 times in the past 6 months. EC approved consents for participation were obtained from each willing and eligible patient before or after PCI who underwent i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 5 8 6 e5 9 2 implantation of BioMatrix stent/s according to standard procedures.
The baseline data were collected from enrolled patients. Implantation of BioMatrixä-Biolimus A9ä eluting stent, BioMatrix in each target lesion during the index procedure was mandatory. The appropriate length and diameter of the stents to be implanted ensuring complete coverage of the lesion were chosen by visual estimate. The stent length ranged between 8 and 28 mm (20.88 AE 5.9), with long length lesion in 30.99% patients, and the nominal stent diameter ranged between 2.2 and 4.0 mm (2.88 AE 0.4), with 2.75 mm in 50.74% patients. Multiple stents were implanted in 66 (19.76%) patients. At least 2 mm overlap was achieved if more than one stent was implanted. Treatment of multiple target vessels (within the same procedure) and staged procedures which occur within 90 days of the initial implant procedure were allowed. All postoperative medical management, including dual antiplatelet therapy, was prescribed according to usual local practice at the discretion of the cardiologist. Data collected by the registry include demographic information, cardiovascular history, comorbidity, lesion and procedure characteristics, and antiplatelet regimens. Patients were followed at 30 days, 6, 12, 24 months by on-site visit with the study physicians or by telephone communication. Interventional cardiologists selected to participate as investigators in this registry were qualified and/or board certified. All the patients were followed for up to 2 years after stent implantation. The study data were verified on-site by the study monitoring group for consistency with source data and to ensure compliance with the protocol as well as with Indian regulatory guidelines.
The drug-eluting coronary stent system (BioMatrixä DES) is comprised of two key components: the stent (which includes Biolimus A9ä incorporated into a polymer coating), and the delivery catheter. A balloon expandable 316L stainless steel stent with polymer coating containing Biolimus A9ä is pre-mounted onto a high pressure, semi-compliant rapid exchange balloon delivery system available in six and nine cell models. The delivery catheter has two radiopaque markers, which fluoroscopically mark the ends of the stent to facilitate proper stent placement. The nominal dosage of Biolimus A9ä for the BioMatrixä stent ranges from 133 to 451 mg depending on stent length. The biodegradable polymer is polylactic acid (PLA), which has been widely used in a variety of medical applications, including orthopedic and dental devices and implants. BioMatrixä is Biosensors' DES having abluminal coated biodegradable polymer. Its abluminal coating (coating only to outer surface) is absorbed after 6e9 months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the proven efficacy of BA9ä and an advanced stent design. As this DES virtually becomes a BMS after 6e9 months, long term safety to the patients is ensured. As there is no polymer present, no drug present after 6e9 months, incidence of ST falls considerably.
An independent clinical events committee adjudicated all MACEs and other serious adverse events developing in the patient population. The committee arbitrated all MACE, other SAE and ST by a systematic review of the data collection forms and by review of the source documents, electrocardiograms, and angiograms in case of suspected stent thrombosis and MACE.
As this is an interim analysis and follow-up is in progress, we have different quantum of follow-up done for patients. Calculations in the paper are based on person-year calculations. Definition of Person-Year: A measurement combining the number of persons and their time contribution in a study. All statistical analyses were performed with SPSS (Version 16.0). Standard descriptive statistics were used for baseline, lesion, and procedural characteristics and for clinical results for all patients. Continuous variables were presented as mean AE SD and range, and categorical variables were presented as numbers and percentages. Descriptive data of the patient population and serious adverse events were compiled as per protocol specified time intervals.
Results
336 patients were enrolled but 334 were followed up. The data of these 334 patients were collected between April 2009 and December 2011 and the results are mentioned below. The interim analysis includes data of 393.2 person-year follow-up. As this is an interim analysis and follow-up is still on, personyear calculation is considered. The mean age was 58.71 AE 9.2 years (range 36e83), comorbidity index was 1.6 AE 1.02, angiographic LVEF(%) was 52.09 AE 11.36% (range 20e81) of which 60 (20.0%) had angiographic LVEF 40%. The patients included were compliant with the eligibility criteria specified in the protocol. Subject age group distribution is described in Table 1 .
Patients' baseline characteristics were as per listed in Table 2 . Around, 19% (65) patients were insulin dependent (IDDM), and 81% (271) patients were non-insulin dependent. Two third of the patients (65.3%) had hypertension, 22.8% had family history of CAD, 16.6% had hypercholesterolemia and 22.3% had suffered previously with MI, 59.1% presented with acute coronary syndrome. A total of 471 BioMatrix DES (1.41 stents/patient) were implanted during the index procedure, to treat a total of 454 lesions with a minimum of 1 and maximum of 6 lesions in 334 patients. The total lesion segment percentage is described in Table 3 . Table 4 shows the number of patients who were taking dual antiplatelet therapy (DAPT) at 1,6 and 12 months.
Non-hierarchy approach was used for counting of MACE. The cumulative rate of MACE is presented in Table 5 and overall stent thrombosis classification (as per ARC definitions) is presented in Table 6 . The incidence rate per 100 person-year was 1.27 for all MACE. There were 3 cases of Re-PCI, but all happened in non-targeted vessel. Two year follow-up of 111 patients (33%) was completed till this interim report. There i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 5 8 6 e5 9 2
were no cases of myocardial infarction and TVR reported in the 2-year follow-up of these 111 patients. The overall incidence of ST, including probable and possible ST was 0.8 per 100 person-year. Definite stent thrombosis occurred in 2 patients only.
Discussion
The interim analysis findings from our e-BioMatrix registry show that BioMatrixä-Biolimus A9ä eluting stent with biodegradable polymer can improve clinical outcomes in diabetic population for up to 2 years. Thus, it contributes significantly towards determining incidence and relative clinical impact of MACE and ST in a large post-marketing surveillance registry, which is one of the largest studies dedicated to diabetic population in India. Diabetic patients are known to be at high-risk for developing cardiovascular disease, increased restenosis, accelerated atherosclerosis and more diffuse diseases. There is always a debate in the medical fraternity regarding use of DES in DM patients. 2 So far, two randomized trials exclusively with diabetic patients have been published, that we know, with an angiographic primary endpoint at 9 months. The first diabetes trial compared SES and BMS in 80 diabetic patients with SES showing TLR of 7.3% and MACE of 11.3% at 9 months. 22 The second is the ISAR-Diabetes registry 23 i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 5 8 6 e5 9 2 have been observed with SES than with paclitaxel-eluting stents in diabetics, particularly over long follow-ups. In the BerneRotterdam registry, the rate of definite ST was 3.6% at 4 years with paclitaxel-eluting stents vs. 2.7% with SES. 27 To date, the BARI trial 25 has been used as a reference for treatment of the diabetic population with cardiovascular disease, which suggested that CABG patients had improved survival compared to angioplasty. At one year, CARDia trial 28 showed no apparent difference between these two treatment options in terms of death or composite of death, non-fatal myocardial infarction and non-fatal stroke which suggested that PCI is a safe alternative to CABG in selected patients with diabetes and multi-vessel coronary artery disease. In this regard, our registry shows a lower definite and probable ST of 0.8 in 393 person-year followup, which is an indication of benefit of BA9 eluting stent in high-risk diabetic population. Supporting this, the LEADERS trial 29 has demonstrated results favoring to BES over SES where 26% were patients with diabetes mellitus. There was 80% relative risk reduction in ST as compared to permanent polymer DES, in the long run (post one year, at least up to four years). Couple of other randomized trials have also supported the established results. 30, 31 More complete strut coverage was observed in an optical coherence tomography substudy 32 of the LEADERS trial patients allocated to BESs at 9 months when compared with SESs suggesting complete endothelialization, which may have impact on clinical outcome and, in particular, on the risk of late stent thrombosis. The potential clinical advantage of BES is expected to fully emerge during longer-term follow-up once the polymer is completely metabolized. Most of the earlier trials have reported significantly higher rates of MACE as compared to our study results. In German Cypher Stent Registry, 33 reported MACE rate in the DM group was significantly higher than in the non-DM group (16.4% vs. 13.0%) at 6 months but lower than expected from historical data with the use of BMS, which was really encouraging. MACE rate in both group (IDDM and NIDDM) were comparable (16.3% vs. 16.4%) at 1-year in the SPIRIT V Diabetic Study, 34 which was a randomized trial in a high-risk group of diabetic patients, implantation of EES compared with PES. These reported rates are much higher than the results we observe in this diabetic registry thus so far. A recently published pooled analyses 35 of various DES or BMS in diabetic patients from 42 randomized trials demonstrated that new generation stents are efficacious and safe. Long term results are unknown, making speculative any assumptions on the potential benefit of DES on mortality and rate of MI in diabetic patients. We have reported 1-and 2-year follow-up data from our registry of diabetic patients who received BioMatrix stents. The incidence of MACE (cardiac death, MI, TVR) and stent thrombosis (definite and probable) were significantly lower (1.27 and 0.8, respectively) than previously published data from trials following diabetic cohort. It also reveals a good overall reported compliance with the administration of antiplatelet therapy after PCI. Thus, in patients with diabetes mellitus, 1 and 2-year outcomes (of 111 patients) from the present interim analysis show substantial benefit after treatment with BioMatrix stents as compared to other devices. BA9ä eluting stents appears to have comparable and favorable clinical outcome in the high-risk diabetic population.
Study limitations
Since patients treated with other than Biolimus stents during the index procedure was an exclusion criterion, no information was collected on other DES, which might have contributed to some degree of selection bias. However, this was the very intention of the study, to know safety and efficacy of BioMatrixä-Biolimus A9ä eluting stent in diabetic patients in India. Secondly, the study design was single-arm with no control arm for direct comparison. However, these limitations are part of any post-marketing surveillance registry.
Conclusion
In conclusion, the 1-and 2-year incidence of MACE in this diabetic population treated with BioMatrix stents is significantly lower as compared to previously published data. The incidence of ST is lower than similar recent registries. These results could be due to unique combination of Biolimus A9 drug (which is 10 times more lipophilic than its analogs), biodegradable polymer PLA and technology of abluminal coating. These support favorable clinical outcomes of using BioMatrix stents as a suitable alternative to contemporary DES during PCI in diabetic patients. Highlights like advanced stent design, highly lipophilic Biolimus A9 drug, biodegradable polymer (PLA) and their application on the abluminal side of the stent could be responsible for such encouraging results of BioMatrix BES. This registry is especially important for Indian set-up, where increasing prevalence of diabetes is a concern.
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